05/28/2026
Can we finally treat concussions instead of simply telling patients to “rest”?
This week on Inside Startup Investing, Oxeia Biopharma CEO Dr. Michael Wyand joins Chris Lustrino to discuss the company’s promising clinical-stage therapy targeting concussion recovery and persistent neurological symptoms.
Topics include:
🧠 The science behind concussion-related brain damage
🧠 How ghrelin may help repair neural pathways
🧠 Oxeia’s 85% responder rate in Phase 2a trials
🧠 The multi-billion-dollar concussion treatment market
🧠 Why brain injury therapeutics may become a major biotech category
An insightful conversation on one of healthcare’s most overlooked challenges.
Oxeia Biopharma CEO Dr. Michael Wyand discusses the company’s breakthrough concussion treatment, Phase 2 clinical results, brain injury recovery science, and the future of neurological therapeutics…